Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, Larkin A, Ballot J, Mahgoub T, Sclafani F, Madden S, Kennedy J, Duffy MJ, Crown J, O'Donovan N. Browne BC, et al. Among authors: larkin a. Breast Cancer Res Treat. 2012 Dec;136(3):717-27. doi: 10.1007/s10549-012-2260-9. Epub 2012 Nov 2. Breast Cancer Res Treat. 2012. PMID: 23117852
EGFR and HER2 inhibition in pancreatic cancer.
Walsh N, Kennedy S, Larkin A, Corkery B, O'Driscoll L, Clynes M, Crown J, O'Donovan N. Walsh N, et al. Among authors: larkin a. Invest New Drugs. 2013 Jun;31(3):558-66. doi: 10.1007/s10637-012-9891-x. Epub 2012 Oct 18. Invest New Drugs. 2013. PMID: 23076814
Predictive biomarkers for dasatinib treatment in melanoma.
Eustace AJ, Kennedy S, Larkin AM, Mahgoub T, Tryfonopoulos D, O'Driscoll L, Clynes M, Crown J, O'Donovan N. Eustace AJ, et al. Oncoscience. 2014 Mar 12;1(2):158-66. doi: 10.18632/oncoscience.20. eCollection 2014. Oncoscience. 2014. PMID: 25594008 Free PMC article.
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J. O'Connor R, et al. Among authors: larkin a. Cancer Chemother Pharmacol. 2007 Jan;59(1):79-87. doi: 10.1007/s00280-006-0240-7. Epub 2006 Apr 27. Cancer Chemother Pharmacol. 2007. PMID: 16642371 Clinical Trial.
Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer.
Dowling P, Pollard D, Larkin A, Henry M, Meleady P, Gately K, O'Byrne K, Barr MP, Lynch V, Ballot J, Crown J, Moriarty M, O'Brien E, Morgan R, Clynes M. Dowling P, et al. Among authors: larkin a. Mol Biosyst. 2015 Mar;11(3):743-52. doi: 10.1039/c4mb00384e. Epub 2014 Dec 8. Mol Biosyst. 2015. PMID: 25483567
308 results